Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "TOFACITINIB CITRATE TABLET" OBTAINS APPROVAL FOR DRUG REGISTRATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"TOFACITINIB CITRATE TABLET"

OBTAINS APPROVAL FOR DRUG REGISTRATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Tofacitinib Citrate Tablet", a drug treating rheumatoid arthritis developed by Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., a subsidiary of the Company, has obtained approval for drug registration granted by the National Medical Products Administration of the People's Republic of China. Such product was the first of its type to obtain approval for drug registration in China and has first completed bioequivalence study. It was filed as Chemicals New Category 4 drug, and is considered to have passed the consistency evaluation.

Tofacitinib Citrate is the world's first small molecule targeted inhibitor of Janus kinase (JAK), for the treatment of rheumatoid arthritis. With its target selectivity, the efficacy and safety of Tofacitinib Citrate are comparable to biological agents. It is also convenient for oral use, low in price and is more acceptable by patients.

Currently, only the branded drug of Tofacitinib Citrate Tablet is available in the Chinese market. The expensive treatment costs have limited the clinical application of such drug to a certain level. The launch of Tofacitinib Citrate Tablet developed by the Group in the future will break the monopoly of foreign pharmaceutical enterprise. The scale of supply and demand of the drug in the Chinese market can also be rapidly expanded, bringing good news to the patients of rheumatoid arthritis and providing desirable social and economic benefits.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairlady

Hong Kong, 9 October 2019

1

As at the date of this announcement, the Board of the Company comprises seven Executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2